Tacrolimus in heart transplant recipients: An overview

BioDrugs

Volumn 21, Issue 3, 2007, Pages 139-143

  Patel, Jignesh K ^a   Kobashigawa, Jon A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR BLOCKING AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG WITHDRAWAL; DYSLIPIDEMIA; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL; UNSPECIFIED SIDE EFFECT;

ANIMALS; CLINICAL TRIALS; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; TACROLIMUS;

EID: 34249706297     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200721030-00001     Document Type: Review

References (27)

1. Behr TM, Richter K, Fischer P, et al. Incidence of humoral rejection in heart transplant recipients treated with tacrolimus or cyclosporine A. Transplant Proc 1998; 30 (5): 1920-1
2. Jurcevic S, Dunn MJ, Crisp S, et al. A new enzyme-linked immunosorbent assay to measure anti-endothelial antibodies after cardiac transplantation demonstrates greater inhibition of antibody formation by tacrolimus compared with cyclosporine. Transplantation 1998; 65 (9): 1197-202
3. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-third Official Adult Heart Trans-plantation Report - 2006. J Heart Lung Transplant 2006; 25 (8): 869-79
4. Goto T, Kino T, Hatanaka H, et al. Discovery of FK-506, a novel immunosuppres-sant isolated from Streptomyces tsukubaensis. Transplant Proc 1987; 19 (5 Suppl. 6): 4-8
5. Migita K, Origuchi T, Kawabe Y, et al. FK506 markedly enhances apoptosis of antigen-stimulated peripheral T cells by down-regulation of Bcl-xL. Transplantation 1999; 68 (7): 1018-23
6. Kaibori M, Sakitani K, Oda M, et al. Immunosuppressant FK506 inhibits inducible nitric oxide synthase gene expression at a step of NF-κB activation in rat hepatocytes. J Hepatol 1999; 30 (6): 1138-45
7. Hamalainen M, Lahti A, Moilanen E. Calcineurin inhibitors, cyclosporin A and tacrolimus inhibit expression of inducible nitric oxide synthase in colon epithelial and macrophage cell lines. Eur J Pharmacol 2002; 448 (2-3): 239-44
8. Wang CH, Ko WJ, Chou NK, et al. Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral. Transplant Proc 2004; 36 (8): 2386-7
9. Armitage JM, Fricker FJ, Del Nido P, et al. The clinical trial of FK 506 as primary and rescue immunosuppression in pediatric cardiac transplantation. Transplant Proc 1991; 23 (6): 3058-60
10. Pham SM, Kormos RL, Hattler BG, et al. A prospective trial of tacrolimus (FK 506) in clinical heart transplantation: intermediate-term results. J Thorac Cardiovasc Surg 1996; 111 (4): 764-72
11. Onsager DR, Canver CC, Jahania MS, et al. Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. J Heart Lung Transplant 1999; 18 (5): 448-55
12. Cantin B, Kwok BW, Shiba N, et al. Post-operative conversion from cyclosporine to tacrolimus in heart transplantation: a single-center experience. J Heart Lung Transplant 2003; 22 (7): 723-30
13. Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999; 18 (4): 336-45
14. Reichart B, Meiser B, Vigano M, et al. European Multicenter Tacrolimus (FK506) Heart Pilot Study: one-year results - European Tacrolimus Multicenter Heart Study Group. J Heart Lung Transplant 1998; 17 (8): 775-81
15. Grimm M, Rinaldi M, Yonan NA, et al. Superior prevention of acute rejection by tacrolimus vs. cyclosporine in heart transplant recipients: a large European trial. Am J Transplant 2006; 6 (6): 1387-97
16. Kobashigawa JA, Patel J, Furukawa H, et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporine in heart transplant patients. J Heart Lung Transplant 2006; 25 (4): 434-9
17. Cooney GF, Jeevanandam V, Choudhury S, et al. Comparative bioavailability of neoral and sandimmune in cardiac transplant recipients over 1 year. Transplant Proc 1998; 30 (5): 1892-4
18. Eisen HJ, Hobbs RE, Davis SF, et al. Safety, tolerability, and efficacy of cyclosporine microemulsion in heart transplant recipients: a randomized, multicenter, double-blind comparison with the oil-based formulation of cyclosporine - results at 24 months after transplantation. Transplantation 2001; 71 (1): 70-8
19. Garlicki M, Czub P, Labus K, et al. Conversion from cyclosporine to tacrolimus improves renal function and lipid profile after cardiac transplantation. Ann Transplant 2006; 11 (1): 24-7
20. Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004; 110 (17): 2694-700
21. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349 (9): 847-58
22. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998; 66 (4): 507-15
23. Kobashigawa JA, Miller LW, Russell SD, et al. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporine with MMF in cardiac transplant patients: 1-year report. Am J Transplant 2006; 6 (6): 1377-86
24. Aguero J, Almenar L, Martinez-Dolz L, et al. Variations in the frequency and type of infections in heart transplantation according to the immunosuppression regimen. Transplant Proc 2006; 38 (8): 2558-9
25. Lubitz SA, Baran DA, Alwarshetty MM, et al. Long-term results of tacrolimus monotherapy in cardiac transplant recipients. J Heart Lung Transplant 2006; 25 (6): 699-706
26. Newark Beth Israel Medical Center. Safety outcomes of lower immunosuppression vs traditional immunosuppression in heart transplant recipients [online]. Available from URL: http://www.clinicaltrials.gov/ct/show/ NCT00299221?.order=1 [Accessed 2007 Apr 2]
27. Alloway R, Vanhaecke J, Yonan N, et al. Conversion of stable heart transplant recipients from twice daily prograf to once daily modified release tacrolimus [abstract]. Transplantation 2006; 82 (1 Suppl. 3): 553